The recent, and quite rapid, approval of Gilead Sciences, Inc. ’s Veklury (remdesivir) highlights the agency’s willingness to prioritize therapies for emerging infectious disease threats. Veklury cle
The following is a list of 43 cGMP warning letters issued to drug manufacturers, biologics manufacturers, testing laboratories, cosmetics manufacturers, compounding pharmacies and repackagers during t